Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 38.3% in July

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 58,489 shares, a drop of 38.3% from the June 30th total of 94,847 shares. Based on an average daily trading volume, of 825,988 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Oncotelic Therapeutics Price Performance

Shares of OTCMKTS OTLC remained flat at $0.04 during midday trading on Friday. The stock had a trading volume of 52,401 shares, compared to its average volume of 316,410. The firm has a market cap of $17.56 million, a PE ratio of 0.07 and a beta of -0.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.11 and a quick ratio of 0.11. The firm has a 50-day moving average price of $0.05 and a 200 day moving average price of $0.05. Oncotelic Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.11.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.